Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Singh, Harjeet ^a   Figliola, Matthew J ^a   Dawson, Margaret J ^a   Olivares, Simon ^a   Zhang, Ling ^a   Yang, Ge ^a   Maiti, Sourindra ^a   Manuri, Pallavi ^a   Senyukov, Vladimir ^a   Jena, Bipulendu ^a   Kebriaei, Partow ^a   Champlin, Richard E ^a   Huls, Helen ^a   Cooper, Laurence J N ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSPOSASE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; ARTIFICIAL CELL; COCULTURE; CONTROLLED STUDY; DNA MODIFICATION; DNA TRANSPOSITION; GAMMA IRRADIATION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PROTEIN EXPRESSION; QUALITY CONTROL; T LYMPHOCYTE; TRANSPOSON; VALIDATION STUDY;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD19; ANTIGENS, CD28; ANTIGENS, CD3; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COCULTURE TECHNIQUES; DNA TRANSPOSABLE ELEMENTS; ELECTROPORATION; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; K562 CELLS; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; MUTANT CHIMERIC PROTEINS; T-LYMPHOCYTES; TRANSPOSASES;

EID: 84878547375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064138     Document Type: Article

References (27)

1. Jena B, Dotti G, Cooper LJ, (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044.
2. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH, (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
4. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828.
5. Cooper LJ JB, Bollard CM, (2012) Good T cells for bad B cells. Blood 119: 2700-2702.
6. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
7. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102.
8. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
9. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. (2013) CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 5: 177ra138.
10. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, et al. (2008) Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68: 2961-2971.
11. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, et al. (2011) Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71: 3516-3527.
12. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z, (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510.
13. Izsvak Z, Ivics Z, (2004) Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther 9: 147-156.
14. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, et al. (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-11004.
15. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, et al. (2013) Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp pp. e50070.
16. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, et al. (2012) Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23: 444-450.
17. Kim DW, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S, (1990) Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91: 217-223.
18. Davies JK, Singh H, Huls H, Yuk D, Lee DA, et al. (2010) Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70: 3915-3924.
19. Rabinovich BA, Ketchem RR, Wolfson M, Goldstein L, Skelly M, et al. (2008) A role for the MHC class I-like Mill molecules in nutrient metabolism and wound healing. Immunol Cell Biol 86: 489-496.
20. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, et al. (2013) Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36: 112-123.
21. Jena B, Maiti S, Huls H, Singh H, Lee DA, et al. (2013) Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials. PLoS ONE 8: e57838.
22. Hollis RP, Nightingale SJ, Wang X, Pepper KA, Yu XJ, et al. (2006) Stable gene transfer to human CD34(+) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol 34: 1333-1343.
23. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, et al. (2006) Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 107: 2643-2652.
24. Mahmoud MS, Fujii R, Ishikawa H, Kawano MM, (1999) Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 94: 3551-3558.
25. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
26. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411-1423.
27. Kim JH, Lee SR, Li LH, Park HJ, Park JH, et al. (2011) High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice. PLoS ONE 6: e18556.